$1,615.25 general Payment -- Regeneron Pharmaceuticals to Dr. Thomas Miller
Regeneron Pharmaceuticals Pays Dermatologist $1615.25 for Services Related to Biktarvy
This page provides a detailed analysis of a $1,615.25 general payment from Regeneron Pharmaceuticals to Dr. Thomas Miller. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $1,615.25 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Thomas Miller |
| NPI Number | 1794780205 |
| Physician Specialty | Dermatology |
| Location | City, IN |
| Date of Payment | 2025-02-18 |
| Related Drug/Device | Biktarvy |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $1.6K general payment to Thomas Miller, a Dermatology specialist in City, IN. The payment was associated with Biktarvy. The payment of $1615.25 to Dr. Thomas Miller from Regeneron Pharmaceuticals is for services other than consulting. This payment is associated with the drug Biktarvy, indicating a potential relationship between the physician and the pharmaceutical company's product. The payment occurred on February 18, 2025, and was made to a dermatologist in Indiana.
Patient Guidance: What This Payment Means for You
If you are a patient of Dr. Miller, this payment indicates a professional relationship with Regeneron Pharmaceuticals concerning the drug Biktarvy. It is advisable to discuss any concerns or questions about your treatment and prescribed medications directly with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments to dermatologists for services other than consulting can vary widely. This specific amount for 'compensation for services other than consulting' in relation to a drug like Biktarvy would need to be compared against industry benchmarks for similar services within the dermatology specialty.
Regulatory Context: Sunshine Act Requirements
This transaction is reported under the Sunshine Act, requiring pharmaceutical companies to disclose payments made to physicians and teaching hospitals. The nature of the payment and the associated drug are key details for regulatory transparency.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- regeneron-pharmaceuticals
- dermatology
- biktarvy
- cms-open-payments
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $1.6K payment for?
This was a general payment of $1.6K from Regeneron Pharmaceuticals to Thomas Miller, categorized as "Compensation for services other than consulting". It was associated with Biktarvy. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Thomas Miller accept pharmaceutical money?
Yes, Thomas Miller received this $1.6K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Thomas Miller's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $1.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Dermatology?
To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Thomas Miller's relationship with Regeneron Pharmaceuticals?
The payment is categorized as 'general', suggesting it's not a specific research grant or speaking fee. This $1.6K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Dermatology?
The nature of the payment, 'Compensation for services other than consulting', is broad and requires further detail to understand the exact service provided.
What should patients do after learning about this payment?
If you are a patient of Dr. Miller, this payment indicates a professional relationship with Regeneron Pharmaceuticals concerning the drug Biktarvy. It is advisable to discuss any concerns or questions about your treatment and prescribed medications directly with your doctor.
What else should I know about this general payment?
The specific drug mentioned, Biktarvy, is a key piece of information linking the payment to a particular pharmaceutical product.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.